Bill Detail
H.R. 1266
Congress: 119
Title
Combating Illicit Xylazine Act
Summary
Combating Illicit Xylazine Act This bill regulates xylazine under the Controlled Substances Act (CSA). Xylazine, also known as tranq, is a nonopioid sedative and pain reliever that is approved for use in animals. Recently, the Drug Enforcement Administration (DEA) has reported an increase in trafficking of fentanyl mixed with xylazine. This bill adds xylazine, including its salts, isomers, and salts of isomers, to schedule III of the CSA. Schedule III controlled substances, including anabolic steroids, buprenorphine, and ketamine, have less potential for abuse than a schedule I or II substance, have a currently accepted medical use, and have low or moderate risk of dependence if abused. Under the bill, manufacturing, distributing, or dispensing xylazine, or possessing with intent to manufacture, distribute, or dispense xylazine for illicit use is subject to criminal penalties under the CSA. The bill also requires xylazine transactions to be tracked in the drug reporting system maintained by the DEA. The bill exempts from registration under the CSA persons and entities that possess xylazine (1) lawfully dispensed by a veterinarian or pharmacy and (2) for an animal or for use in certain animal-control or wildlife programs. The bill also exempts xylazine manufacturers from the CSA's physical security requirements. Finally, the bill requires the DEA, in coordination with the Food and Drug Administration, to report on (1) the prevalence and impact of illicit xylazine use in the United States, and (2) updated information on the prevalence and proliferation of xylazine trafficking and misuse in the United States.
Sponsor
Rep. Jimmy Panetta [D-CA-19]
Status
Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 623.
Status as of Nov 15, 2026, 10:22 PM · synced 23h ago
Introduced
2025-02-12
Data source mode: cache
Bill Engagement
Combating Illicit Xylazine Act This bill regulates xylazine under the Controlled Substances Act (CSA).
Lobbyists on the case
These are cached disclosure mentions, not verified current representation or confirmed event attendance.
- Steptoe LLP1 filing · 4 lobs
- Rowan Bost2026 Q3Steptoe LLP · Legislative Aide, Office of Senator Susan Collins; Legislative Correspondent, Office of Senator S…
- Jack Buttarazzi2026 Q3
Limited preview · paid intelligence
Keep the intelligence current—not just this one record.
Unlock every organization and lobbyist filing on this bill, the complete event and issue map, private team positions, and recurring movement alerts across the portfolio.
Federal Intelligence is $2,500 one-time for three months, or $9,000 for twelve months prepaid, for one named user. Full tracked federal calendar, connected organization/bill/disclosure research, and a private workspace. Fixed terms; no automatic renewal. No demo or scope email is required for standard access.
SEE A FINISHED HEALTHCARE EXAMPLE
Three days of Hill visits. Two Medicare access questions.
A separate, source-linked editorial example—not a dossier about this bill, an endorsement, or a claim of participation. The full records stay paid.
Read the finished healthcare brief →After verified successful payment, access is activated within one business day and a secure setup link is emailed. Your term starts at activation. These links do not charge you or unlock records. A free alert subscription does not grant full access.